Impact of exogenous testosterone on mood: A systematic review and meta-analysis of randomized placebo-controlled trials

Annals of Clinical Psychiatry

Volumn 26, Issue 1, 2014, Pages 19-32

  Amanatkar, Hamid R ^a   Chibnall, John T ^a   Seo, Byung Woun ^b   Manepalli, Jothika N ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ABBVIE INC   (United States)

Author keywords

Dehydroepiandrosterone; Hypogonadism; Major depression; Meta analysis; Subthreshold depression; Testosterone

Indexed keywords

PRASTERONE; TESTOSTERONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; EFFECT SIZE; HUMAN; MAJOR DEPRESSION; MALE; MEDLINE; META ANALYSIS; MOOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; DEPRESSION; MIDDLE AGED; REVIEW;

DEPRESSION; DEPRESSIVE DISORDER, MAJOR; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE;

EID: 84906999585     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hor-mones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589-598.
2. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
3. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64:682-696.
4. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007;36:333-348.
5. Dandona P, Dhindsa S, Chaudhuri A, et al. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med. 2008;8:816-828.
6. Fernandez-Egea E, Garcia-Rizo C, Miller B, et al. Testosterone in newly diagnosed, antipsychotic-naive men with nonaffective psychosis: a test of the accelerated aging hypothesis. Psychosom Med. 2011;73:643-647.
7. Gorobets LN, Matrosova MI. Specialties of prolactin secretion and peripheral reproductive sex hormones in patients with of first episode of schizophrenia [in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110:17-22.
8. Levenson JL. Psychosomatic medicine. In: Tasman A, Key J, Lieberman JA, et al, eds. Psychiatry. London, United Kingdom: Wiley; 2008:2505.
9. Schweiger U, Deuschle M, Weber B, et al. Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med. 1999;61:292-296.
10. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241-4247.
11. Itoh N, Tsukamoto T. Clinical aspects of partial andro-gen deficiency of aging male (PADAM) [in Japanese]. Clin Calcium. 2003;13:1432-1437.
12. Tracz MJ, Sideras K, Boloña ER, et al. Clinical review: testosterone use in men and its effects on bone health: a systematic review and meta-analysis of random-ized placebo-controlled trials. J Clin Endocrinol Metab. 2011;91:2011-2016.
13. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63:381-394.
14. Boloña ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled tri-als. Mayo Clin Proc. 2007;82:20-28.
15. Shores MM, Sloan KL, Matsumoto AM, et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61:162-167.
16. Aydogan U, Aydogdu A, Akbulut H, et al. Increased frequency of anxiety, depression, quality of life, and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions. Endocr J. 2012;59:1099-1154.
17. Khera M, Bhattacharya RK, Blick G, et al. The effects of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012;15:14-21.
18. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91:4335-4343.
19. Lackner J, Rücklinger E, Schatzi G, et al. Are there symptom-specific testosterone thresholds in aging men. BJU Int. 2011;108:1310-1315.
20. Guyton AC, Hall JE. Reproductive and hormonal func-tions of the male (and function of the pineal gland). In: Guyton AC, Hall JE, eds. Textbook of medical physiology. Philadelphia, PA: Saunders; 2000:922-928.
21. Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for treatment of male hypogo-nadism in a worldwide sample of 1,438 men. J Sex Med. 2013;10:579-588.
22. Seidman SN, Roose SP. Sexual function and depres-sion. Curr Psychiatry Rep. 2001;3:202-208.
23. Nofzinger EA, Thase ME, Reynolds CF 3rd, et al. Sexual function in depressed men. Assessment by self-report, behavioral, and nocturnal penile tumescence mea-sures before and after treatment with cognitive behavior therapy. Arch Gen Psychiatry. 1993;50:24-30.
24. Araujo AB, Durante R, Feldman HA, et al. The relation-ship between depressive symptoms and male erectile dys-function: cross sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60:458-465.
25. Rizvi SJ, Kennedy SH, Ravindran LN, et al. The rela-tionship between testosterone and sexual function in depressed and healthy men. J Sex Med. 2010;7:816-825.
26. Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1999;84:573-577.
27. Almeida OP, Yeap BB, Hankey GJ, et al. Low free tes-tosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry. 2008;65:283-289.
28. Pope HG Jr, Amiaz R, Brennan BP, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol. 2010;30:126-134.
29. Liberati A, Altman DG, Tetzlass J, et al. The PRISMA statement for reporting systematic reviews and meta-anal-ysis of studies that evaluate health care interventions: expla-nation and elaboration. J Clin Epidemiol. 2009;62:e1-34.
30. Posternak MA, Zimmerman M. Short-term sponta-neous improvement rates in depressed outpatients. J Nerv Ment Dis. 2000;188:799-804.
31. Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7:2572-2582.
32. Grinspoon S, Corcoran C, Stanley T, et al. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Endocrinol Metab. 2000;85:60-65.
33. Haren MT, Wittert GA, Chapman IM, et al. Effects of oral testosterone undecanoate on visuospatial cognition, mood, and quality of life in elderly men with low-normal gonadal status. Maturitas. 2005;50:124-133.
34. Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006;63:177-185.
35. Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18:20-24.
36. Pope HG Jr, Kouri EM, Hudson JI. Effects of supra-physiologic doses of testosterone on mood and aggression in normal men. Arch Gen Psychiatry. 2000;57:133-140.
37. Pope HG Jr, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:105-111.
38. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:141-147.
39. Rabkin JG, Wagner GJ, McElhiney MC, et al. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol. 2004;24:379-385.
40. Rabkin JG, McElhiney MC, Rabkin R, et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry. 2006;163:59-66.
41. Seidman SN, Miyazaki M, Roose SP. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J Clin Psychopharmacol. 2005;25:584-588.
42. Seidman SN, Roose SP. The sexual effects of testoster-one replacement in depressed men: randomized placebo-controlled clinical trial. J Sex Marital Ther. 2006;32:267-273.
43. Seidman SN, Orr G, Raviv G, et al. Effects of testoster-one replacement in middle-aged men with dysthymia: a randomized placebo-controlled clinical trial. J Clin Psychopharmacol. 2009;29:216-221.
44. Shores MM, Kivlahan DR, Sadak TI, et al. A random-ized double-blind placebo-controlled study of testoster-one treatment in hypogonadal older men with subthresh-old depression (dysthymia or minor depression). J Clin Psychiatry. 2009;70:1009-1016.
45. Zhang X, Liu Z, Hu X, et al. Androgen replace-ment therapy improves psychological distress and health-related quality of life in late onset hypogonad-ism patients in Chinese population. Chin Med J (Engl). 2012;125:3806-3810.
46. Cavallini G, Caracciolo S, Vitali G, et al. Carnitine ver-sus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004;63:641-646.
47. Knapp PE, Storer TW, Herbst KL, et al. Effects of a sup-raphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab. 2008;294:E1135-E1143.
48. McNicholas TA, Dean JD, Mulder H, et al. A novel tes-tosterone gel formulation normalizes androgen levels in hypogonadal men, with improvement in body composi-tion and sexual function. BJU Int. 2003;91:69-74.
49. O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab. 2004;89:2837-2845.
50. Dean JD, Carnegie C, Rodzvilla J, et al. Long-term effects of Testim 1% testosterone gel in hypogonadal men. Rev Urol. 2005;7:87-94.
51. Steidle C, Schwartz S, Jacoby K, et al; North American AA2500 T Gel Study Group. AA2500 testosterone gel nor-malizes androgen levels in aging males with improve-ments in body composition and sexual function. J Clin Endocrinol Metabol. 2002;88:2673-2681.
52. Kenny AM, Fabregas G, Song C, et al. Effects of testos-terone on behavior, depression and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci. 2004;59:75-78.
53. Schmidt PJ, Berlin KL, Danaceau MA, et al. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry. 2004;61:997-1004.
54. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month ran-domized controlled trial. J Clin Endocrinol Metab. 1997; 82:1661-1667.
55. Jockenhövel F. Testosterone therapy-what, when and to whom. Aging Male. 2004;7:319-324.
56. Bhasin S, Cunningham GR, Hayes FJ, et al; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:2536-2559.
57. Wu FC, Tajar A, Beynon JM, et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010:363:123-135.
58. Seidman SN, Roose SP, Rosen RC. Sexual dysfunction and pharmacological treatments: biological interactions. In: Charney DS, Nestler EJ, eds. Neurobiology of mental illness. New York, NY: Oxford University Press; 2009:1332.
59. Taniguchi H, Kawa G, Kinoshita H, et al. Symptomatic change in Japanese hypogonadal patients several years after androgen replacement therapy. Aging Male. 2011; 14:190-194.